An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis
An Observational Study of the Efficacy of RoActemra in Smoking vs Non-smoking Patients With Rheumatoid Arthritis.
Sponsor: Hoffmann-La Roche
This observational or N/A phase trial investigates Rheumatoid Arthritis and is currently completed. Hoffmann-La Roche leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bergen, Norway , Drammen, Norway , Eskilstuna, Sweden , Falun, Sweden , Farsta, Sweden , Gjettum, Norway , Gothenburg, Sweden , Kalmar, Sweden , Karlstad, Sweden , Kristiansand, Norway and 18 more locations